Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Overview: Amgen is a global biotechnology company focused on discovering, developing, and marketing human therapeutics. The reporting period reflects the full-year integration of Immunex Corporation, acquired in July 2002 for approximately $17.8 billion. Key therapeutic areas include hematology, oncology, and inflammation. Major products include EPOGEN, Aranesp, Neulasta, NEUPOGEN, and ENBREL (co-promoted with Wyeth).
Key Financial Metrics
| Metric (in millions) | 2003 | 2002 | 2001 |
|---|---|---|---|
| Total Revenues | $8,356.0 | $5,523.0 | $4,015.7 |
| Product Sales | $7,868.2 | $4,991.2 | $3,511.0 |
| Net Income (Loss) | $2,259.5 | $(1,391.9) | $1,119.7 |
| Diluted EPS | $1.69 | $(1.21) | $1.03 |
| Operating Cash Flow | $3,566.6 | $2,248.8 | $1,480.2 |
| Total Assets | $26,176.5 | $24,456.3 | $6,443.1 |
| Long-Term Debt | $3,079.5 | $3,047.7 | $223.0 |
| Stockholders' Equity | $19,389.1 | $18,286.0 | $5,217.2 |
Liquidity: Cash, cash equivalents, and marketable securities totaled $5,122.9 million at year-end 2003. The company maintains a $5.0 billion stock repurchase program authorized in December 2003.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 51% to $8.36 billion, driven primarily by strong demand for Aranesp (up 271% to $1.54 billion), Neulasta (up 171% to $1.26 billion), and ENBREL (up 259% to $1.30 billion, reflecting full-year inclusion post-acquisition).
- Profitability: The company returned to profitability with $2.26 billion in net income, reversing a $1.39 billion loss in 2002. The 2002 loss was primarily due to a one-time $2.99 billion write-off of acquired in-process research and development (IPR&D) from the Immunex acquisition.
- Expenses: R&D expenses rose 48% to $1.66 billion due to higher outside costs (including an $86.5 million upfront fee to Biovitrum) and staff costs. SG&A expenses increased 34% to $1.95 billion, largely due to Wyeth profit sharing on ENBREL sales and marketing support for new products.
- Debt Structure: Long-term debt increased significantly in 2002 due to the issuance of $3.95 billion in 30-year zero-coupon convertible notes. As of 2003, the carrying value was $2.88 billion.
Guidance, Outlook, and Risks
Outlook: Management expects near-term growth to be driven by Aranesp, Neulasta, and ENBREL. Capital expenditures for 2004 are estimated between $1.3 billion and $1.5 billion, primarily for manufacturing expansions in Rhode Island and Puerto Rico.
Key Risks and Contingencies:
- Reimbursement: Sales depend heavily on third-party payors (Medicare, Medicaid, private insurers). The Medicare Prescription Drug Improvement and Modernization Act of 2003 may impact reimbursement rates.
- Supply Constraints: ENBREL supply is significantly dependent on contract manufacturer Boehringer Ingelheim Pharma KG (BI Pharma). Supply interruptions could materially affect sales.
- Patent Expirations: European patents for erythropoietin and G-CSF expire in 2004 and 2006, respectively, potentially inviting competition.
- Legal Proceedings: The company faces litigation regarding Average Wholesale Price (AWP) reporting and patent disputes (e.g., Transkaryotic Therapies/Aventis). Government investigations into pricing practices are ongoing.
Investor Verification Checklist
- ENBREL Supply Chain: Verify the status of manufacturing capacity at BI Pharma and the new Rhode Island facility to ensure no supply constraints impact future revenue.
- Reimbursement Policy Changes: Monitor the implementation details of the 2003 Medicare Modernization Act and its specific impact on EPOGEN and Aranesp reimbursement rates.
- Patent Litigation Outcomes: Track the resolution of the Transkaryotic Therapies/Aventis litigation and the Israel Bio-Engineering Project lawsuit regarding ENBREL patent ownership.
- Product Conversion Rates: Assess the rate of patient conversion from NEUPOGEN to Neulasta, which impacts NEUPOGEN sales decline and Neulasta growth sustainability.
- Convertible Notes: Review the terms of the $3.95 billion convertible notes, specifically the potential for cash or stock repurchase requirements starting March 1, 2005.